Genomics Center leads ovarian cancer projects

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

The National Functional Genomics Center has launched a consortium that will undertake two projects: A biologically-driven analysis of ovarian cancer cell lines and a trial that uses molecular profiling to target chemotherapy.

The National Functional Genomics Center has launched a consortium that will undertake two projects: A biologically-driven analysis of ovarian cancer cell lines and a trial that uses molecular profiling to target chemotherapy.

The first project will profile ovarian cancer cells and ovarian cancer stem cells. The researchres will characterize gene expression, and oncogene activation of copy number and point mutations, in preclinical models. The group also will characterize platinum resistance and the interaction between ovarian cancer cells and the immune environment.

The NFGC is also funding a clinical trial in which molecular data from an individual woman’s ovarian cancer will be used to to select a chemotherapy regimen. The trial will be led by Johnathan Lancaster, MD, PhD, at the H. Lee Moffitt Cancer Center in Tampa, Fla.

Recent Videos
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Related Content